|Bid||150.12 x 800|
|Ask||150.29 x 800|
|Day's Range||141.57 - 152.32|
|52 Week Range||38.88 - 152.32|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||126.50|
Dr. Kristen Choi, PhD, MS, RN, Assistant Professor, UCLA School of Nursing, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on the coronavirus.
Achieving herd immunity through mass vaccination involves a delicate — sometimes tricky — dance with side effects, public opinion and virus variants. The rollout of coronavirus vaccines has not been without challenges, but the government’s goal to not rely on just one vaccine has limited the scope of a setback involving any one product. The Food and Drug Administration and the Centers for Disease Control and Prevention recommended a pause in the use of the Johnson & Johnson vaccine this week as they examine six severe cases of blood clots.
China is planning to authorize the COVID-19 vaccine developed by Germany's BioNTech SE by July, the Wall Street Journal reported on Friday, citing people familiar with the matter. Chinese officials are reviewing clinical-trial data for the vaccine and are expected to authorize it for domestic use within the next 10 weeks, the report said. BioNTech said in a statement that it does not speculate on timings of approvals.